TDMS Study 05161-06 Pathology Tables
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
MICE/FINAL#1
Facility: Southern Research Institute
Chemical CAS #: 23246-96-0
Lock Date: 11/17/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50
Early Deaths
Moribund Sacrifice 9 25
Natural Death 3 8
Accidently Killed 4
Survivors
Natural Death 1
Terminal Sacrifice 34 16
Animals Examined Microscopically 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (45)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Intestine Large, Colon (49) (47)
Intestine Large, Cecum (48) (47)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Intestine Small, Jejunum (43) (45)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (46) (46)
Liver (49) (50)
Cholangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 7 (14%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 7 (14%)
Hepatocellular Adenoma, Multiple 2 (4%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Sarcoma, Multiple 1 (2%)
Mesentery (23) (29)
Carcinoma, Metastatic, Kidney 1 (3%)
Hemangioma 1 (3%)
Histiocytic Sarcoma 1 (4%) 1 (3%)
Sarcoma 1 (3%)
Sarcoma, Multiple 1 (4%)
Pancreas (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Multiple 1 (2%)
Page 2
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (50) (50)
Stomach, Forestomach (49) (49)
Stomach, Glandular (49) (48)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Adrenal Medulla (49) (49)
Pituitary Gland (48) (49)
Adenoma 1 (2%)
Pars Distalis, Adenoma 5 (10%) 1 (2%)
Thyroid Gland (49) (50)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (49)
Duct, Carcinoma 1 (2%)
Ovary (49) (48)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Luteoma 1 (2%)
Uterus (49) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Adenoma 1 (2%)
Endometrium, Polyp Stromal 1 (2%)
Vagina (2)
Sarcoma 1 (50%)
Page 3
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50)
Carcinoma, Metastatic, Kidney 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (7) (15)
Iliac, Histiocytic Sarcoma 1 (14%)
Mediastinal, Histiocytic Sarcoma 1 (14%) 1 (7%)
Pancreatic, Histiocytic Sarcoma 1 (14%)
Pancreatic, Sarcoma 1 (14%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Mandibular (48) (47)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (48) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Thymus (49) (39)
Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (50)
Adenoma 1 (2%)
Carcinoma 2 (4%)
Skin (50) (50)
Subcutaneous Tissue, Sarcoma 3 (6%) 2 (4%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50)
Cranium, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
Skeletal Muscle (1) (3)
Histiocytic Sarcoma 1 (33%)
Sarcoma, Multiple 1 (100%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 9 (18%)
Alveolar/Bronchiolar Carcinoma 3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mediastinum, Carcinoma, Metastatic, Kidney 1 (2%)
Nose (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (5)
Adenoma 2 (50%) 3 (60%)
Carcinoma 2 (50%) 1 (20%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Osteosarcoma 1 (2%)
Ureter (1)
Carcinoma, Metastatic, Kidney 1 (100%)
Urinary Bladder (50) (48)
Sarcoma 1 (2%)
Page 5
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 7 (14%) 9 (18%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 3.0
MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 31 33
Total Primary Neoplasms 49 49
Total Animals with Benign Neoplasms 15 17
Total Benign Neoplasms 19 21
Total Animals with Malignant Neoplasms 21 20
Total Malignant Neoplasms 30 28
Total Animals with Metastatic Neoplasms 2 3
Total Metastatic Neoplasm 3 6
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50 50
Early Deaths
Moribund Sacrifice 4 6 3 6 13
Natural Death 6 3 7 6 17
Accidently Killed 1
Survivors
Terminal Sacrifice 39 41 40 38 18
Natural Death 2
Animals Examined Microscopically 50 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50) (50)
Gallbladder (44) (43) (36) (41) (38)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (44) (47) (44) (48) (39)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Serosa, Hepatoblastoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (45) (48) (47) (47) (40)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (45) (47) (44) (47) (39)
Carcinoma 1 (2%) 2 (4%)
Intestine Small, Ileum (44) (49) (44) (47) (41)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) 14 (28%)
Hemangiosarcoma, Multiple 17 (34%)
Hepatoblastoma 3 (6%) 2 (4%) 1 (2%)
Hepatocellular Carcinoma 7 (14%) 11 (22%) 10 (20%) 15 (30%) 3 (6%)
Hepatocellular Carcinoma, Multiple 16 (32%) 10 (20%) 9 (18%) 5 (10%)
Hepatocellular Adenoma 13 (26%) 10 (20%) 12 (24%) 5 (10%)
Hepatocellular Adenoma, Multiple 3 (6%) 8 (16%) 2 (4%)
Histiocytic Sarcoma 3 (6%) 2 (4%) 3 (6%)
Leiomyosarcoma 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mesentery (12) (10) (9) (14) (6)
Hemangiosarcoma 1 (17%)
Hemangiosarcoma, Metastatic, Liver 1 (8%)
Page 8
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hepatoblastoma, Metastatic, Liver 1 (7%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (14%)
Histiocytic Sarcoma 2 (20%) 3 (21%)
Leiomyosarcoma 1 (11%)
Sarcoma, Metastatic, Skeletal Muscle 1 (17%)
Pancreas (49) (50) (50) (50) (48)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 3 (6%) 1 (2%)
Leiomyosarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50) (50)
Stomach, Forestomach (49) (50) (50) (50) (49)
Leiomyosarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (47) (48) (49) (49) (46)
Leiomyosarcoma 1 (2%)
Tooth (24) (15) (18) (4) (4)
Peridontal Tissue, Fibrosarcoma 1 (6%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50) (50)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (50) (50) (49)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Adenoma, Multiple 1 (2%)
Carcinoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Capsule, Adenoma 3 (6%) 7 (14%) 3 (6%) 1 (2%) 1 (2%)
Capsule, Leiomyosarcoma 1 (2%)
Adrenal Medulla (49) (49) (49) (50) (48)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (50) (50) (48)
Adenoma 3 (6%)
Pituitary Gland (49) (47) (48) (46) (47)
Pars Distalis, Adenoma 1 (2%) 1 (2%)
Page 9
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (50) (49) (50) (50)
Follicular Cell, Adenoma 2 (4%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (1) (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1)
Histiocytic Sarcoma 1 (100%)
Epididymis (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (50) (50) (50) (50) (50)
Adenoma 1 (2%)
Prostate (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Testes (50) (50) (50) (50) (50)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
Sarcoma 1 (2%)
Lymph Node (2) (3) (4) (7) (4)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (25%)
Bronchial, Hepatoblastoma, Metastatic, Liver 1 (14%)
Inguinal, Histiocytic Sarcoma 1 (33%)
Mediastinal, Histiocytic Sarcoma 2 (67%) 1 (14%)
Renal, Histiocytic Sarcoma 2 (67%) 1 (14%)
Lymph Node, Mandibular (49) (48) (49) (49) (44)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (49) (48) (48) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Page 10
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 3 (6%) 4 (8%)
Leiomyosarcoma 1 (2%)
Spleen (49) (49) (50) (50) (49)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Thymus (42) (46) (45) (43) (43)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50) (49)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (1)
Hemangiosarcoma 1 (50%)
Sarcoma, Multiple 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50) (50)
Meninges, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 9 (18%) 10 (20%) 5 (10%) 12 (24%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (8%) 1 (2%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 6 (12%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 4 (8%) 2 (4%) 4 (8%) 1 (2%) 4 (8%)
Carcinoma, Metastatic, Harderian Gland 2 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%) 5 (10%)
Page 11
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 6 (12%) 4 (8%) 8 (16%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%) 1 (2%)
Nose (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (6) (1) (7) (8) (3)
Adenoma 4 (67%) 1 (100%) 6 (86%) 8 (100%) 2 (67%)
Carcinoma 2 (33%) 1 (14%) 1 (13%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50) (50) (50)
Carcinoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 4 (8%)
Capsule, Hemangiosarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 3 (6%) 4 (8%)
Lymphoma Malignant 3 (6%) 2 (4%) 1 (2%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05161-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RIDDELLIINE Date: 11/30/00
Route: GAVAGE Time: 08:16:00
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 0.1 0.3 1.0 3.0
MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY MG/KG/DY
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 44 45 47 42 47
Total Primary Neoplasms 85 79 82 64 69
Total Animals with Benign Neoplasms 32 27 28 23 17
Total Benign Neoplasms 42 39 37 27 20
Total Animals with Malignant Neoplasms 29 31 30 33 41
Total Malignant Neoplasms 43 40 45 37 49
Total Animals with Metastatic Neoplasms 8 6 5 10 7
Total Metastatic Neoplasm 10 6 5 20 11
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------